Proposition 38 will ask voters to approve borrowing $8.4 billion to support medical research in immunology and immunotherapy.
ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the ...
Protagonist Therapeutics (PTGX), and Shattuck Labs (STTK) as its top picks in the emerging technology sector. For Nektar, the firm cited the novel Treg mechanism used in its phase 3 asset ...
One of the most exciting developments is the growth of immune-based therapies. CAR-T cell therapies involve modifying a ...
3d
[The Seven Wonders of Immunology I Felt: Part 1] Why doesn't the immune system attack its own body?
When researching the immune system, I sometimes encounter mysterious questions."Why does something like this happen?"The more ...
Basic studies led to clinical and translational advances that no one could have predicted,” Robert Gallo writes of his work ...
Kymera Therapeutics (KYMR) eyes pivotal BROADEN2 Phase 2b data for KT-621, a STAT6 degrader in atopic dermatitis—upside vs.
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet ...
“When humans migrated around the world, our gut microbiomes came with us. We're now losing many of those ancient microbial ...
When two people become ill at the same time, they often experience different symptoms. For instance, during the COVID-19 ...
The Frontline of mRNA Vaccines, Actemra, CAR-T Cells, and Gut Immunity" by Tadamitsu Kishimoto and Akira Nakajima (Kodansha ...
The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results